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Summary
Background Antibiotic resistance is a global public health threat. Antibiotics are very commonly prescribed for children 
presenting with uncomplicated lower respiratory tract infections (LRTIs), but there is little evidence from randomised 
controlled trials of the effectiveness of antibiotics, both overall or among key clinical subgroups. In ARTIC PC, we 
assessed whether amoxicillin reduces the duration of moderately bad symptoms in children presenting with 
uncomplicated (non-pneumonic) LRTI in primary care, overall and in key clinical subgroups.
Methods ARTIC PC was a double-blind, randomised, placebo-controlled trial done at 56 general practices in England. 
Eligible children were those aged 6 months to 12 years presenting in primary care with acute uncomplicated LRTI 
judged to be infective in origin, where pneumonia was not suspected clinically, with symptoms for less than 21 days. 
Patients were randomly assigned in a 1:1 ratio to receive amoxicillin 50 mg/kg per day or placebo oral suspension, in 
three divided doses orally for 7 days. Patients and investigators were masked to treatment assignment. The primary 
outcome was the duration of symptoms rated moderately bad or worse (measured using a validated diary) for up to 28 
days or until symptoms resolved. The primary outcome and safety were assessed in the intention-to-treat population. 
The trial is registered with the ISRCTN Registry (ISRCTN79914298).
Findings Between Nov 9, 2016, and March 17, 2020, 432 children (not including six who withdrew permission for use 
of their data after randomisation) were randomly assigned to the antibiotics group (n=221) or the placebo group 
(n=211). Complete data for symptom duration were available for 317 (73%) patients; missing data were imputed for 
the primary analysis. Median durations of moderately bad or worse symptoms were similar between the groups 
(5 days [IQR 4–11] in the antibiotics group vs 6 days [4–15] in the placebo group; hazard ratio [HR] 1·13 [95% CI 
0·90–1·42]). No differences were seen for the primary outcome between the treatment groups in the five prespecified 
clinical subgroups (patients with chest signs, fever, physician rating of unwell, sputum or chest rattle, and short of 
breath). Estimates from complete-case analysis and a per-protocol analysis were similar to the imputed data analysis.
Interpretation Amoxicillin for uncomplicated chest infections in children is unlikely to be clinically effective either 
overall or for key subgroups in whom antibiotics are commonly prescribed. Unless pneumonia is suspected, clinicians 
should provide safety-netting advice but not prescribe antibiotics for most children presenting with chest infections.
Funding National Institute for Health Research.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Acute respiratory tract infections (RTI) are among the 
commonest conditions managed in primary care.1 WHO 
and the UK Department of Health2 recognise that 
antibiotic resistance is an increasingly serious public 
health problem, with rising resistance rates for a range of 
antibiotics, and a clear relationship between primary care 
antibiotic prescribing (80% of all antibiotic prescribing) 
and antibiotic resistance at national3 and individual4–6 
levels. The costs of resistance are also often not included 
in current estimates of cost-effectiveness and these can 
have an important impact on estimates.7 Although 
consultation rates and antibiotic prescription rates for 
upper RTI (URTI) or chest infections declined sharply in 
the late 1990s until the early 2000s,8 overall antibiotic use 
increased again, decreased 15% between 2015 and 2019,9 
and allowing for the reduced consultation rates, was 
6·71% higher again during the COVID-19 pandemic than 
during previous years.10 Children have higher consultation 
rates for RTI than adults, and even when antibiotic 
prescribing was at its lowest, most children labelled as 
having URTI or chest infection still were prescribed 
antibiotics in the UK,11 with similar high rates of 
prescribing for RTIs among children internationally.12,13 
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Data from our observational study in antibiotic 
prescribing confirmed that at least 40% of children are 
prescribed antibiotics for chest infections,14 which 
translates to 2 million prescriptions for antibiotics for 
cough in this age group in the UK,11,15 or about GBP 
£30 million annually in direct consultation and 
dispensing costs, not including the indirect costs incurred 
by so-called medi calising illness in the family and wider 
social networks, where perceived benefit of antibiotics 
because of symptom resolution, even if unrelated, leads 
to individuals being more likely to seek reconsultation in 
future, even if antibiotics are ineffective.16,17
Although trials among adults suggest only modest 
benefit, even among important clinical subgroups,18 
there is scarce randomised, placebo-controlled evidence 
to support or dispute the common use of antibiotics in 
children with chest infections: only one trial in a 
Cochrane review of antibiotic prescribing included 
young children aged 3 years and older.17,19 It might be 
that antibiotics in children also have little benefit given 
the similarity of presentation of lower RTI (LRTI) to 
adults; however, the differences in immunity and 
anatomy between adults and children prohibit simply 
applying evidence derived in adults to the management 
of children.20 Parents want help managing symptoms 
and improving the course of illness and are concerned 
about significant adverse outcomes.21,22 Prescribing 
antibiotics could potentially reduce societal costs (eg, 
out-of-pocket expenses and time off work). Clinicians 
also face the difficulty of knowing whether patients 
presenting are an average patient, given the variation in 
pathophysiology and disease severity, and prescribing 
decisions are made by general practitioners (GPs) using 
traditional but non-evidence-based clinical signs like 
sputum production, fever, chest signs, and feeling 
unwell.23–26
Here, we report the ARTIC PC trial, which aimed to test 
the hypothesis that amoxicillin reduces the duration of 
moderately bad symptoms in children presenting with 
uncomplicated (non-pneumonic) LRTI in primary care, 
overall and in key clinical subgroups. We also did a parallel 
observational study where the same measures and 
outcomes were collected (to be fully reported separately).
Methods
Study design
ARTIC PC is a double-blind, randomised, placebo-
controlled, parallel-group trial of amoxicillin versus 
placebo for children presenting with chest infections in 
primary care, done at 56 general practices in England.
The trial protocol was approved by the South West-
Central Bristol Research Ethics Committee (reference 
15/SW/0300).
Participants 
Children aged between 6 months and 12 years presenting 
to primary care with an acute LRTI (as defined in several 
previous cohorts and trials as having an acute cough as 
the predominant symptom) judged by the GP to be 
infective in origin, lasting less than 21 days, and with 
other symptoms or signs localising to the lower 
respiratory tract (shortness of breath, sputum, or pain) 
were eligible for the trial.27–30 These inclusion criteria 
reflect the clinical criteria used in daily practice to 
diagnose acute bronchitis,31 were used in the previous 
Cochrane review,19 and are the key drivers of prescribing.23,24
Exclusion criteria were non-infectious cause (eg, hay 
fever or a non-infective exacerbation of asthma) or 
almost certain viral cause (croup, where antibiotics are 
not commonly prescribed), as judged by the clinician; 
individuals who are immune compromised; and 
antibiotic use in the previous 30 days. Children for whom 
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Research in context
Evidence before this study
We used the Cochrane systematic review as the basis for 
assessing the evidence. The authors of the Cochrane review 
searched for primary research of randomised controlled trials 
with no language restrictions in CENTRAL 2016, issue 11 
(accessed Jan 13, 2017), MEDLINE (1966 to Jan week 1, 2017), 
Embase (1974 to Jan 13, 2017), and LILACS (1982 to Jan 13, 
2017); and searched the WHO International Clinical Trials Registry 
Platform and ClinicalTrials.gov on April 5, 2017. Search terms are 
in the appendix (p 13). The review of antibiotics for acute 
bronchitis documented that antibiotics have a modest effect on 
cough duration (seven studies, 2776 participants, mean 
difference –0·46 days [95% CI –0·87 to –0·04]). However, the 
trials in the Cochrane review included very few children and the 
differences in immunity and anatomy between adults and 
children prohibit simply applying evidence derived in adults to 
the management of children.
Added value of this study
This study confirms that antibiotics (amoxicillin) do not 
provide a clinically important benefit for symptom duration 
among children presenting with uncomplicated lower 
respiratory tract infections (antibiotic median 5 days vs 
placebo 6 days, hazard ratio 1·13 [95% CI 0·90 to 1·42]), nor in 
the key clinical subgroups that clinicians commonly prescribe 
for (those with chest signs, fever, physician rating of unwell, 
sputum or chest rattle, and shortness of breath).
Implications of all the available evidence
The data from our study and previous studies suggest that 
unless pneumonia is suspected, clinicians should provide so-
called safety-netting advice (ie, explain what illness course to 
expect and when it would be necessary to reattend) but not 
prescribe antibiotics for most children presenting with chest 
infections.
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the clinician did not have equipoise (the clinician judged 
that pneumonia was likely or children judged to be 
severely ill) were not enrolled, but they were eligible to 
enter the parallel observational study. Patients that were 
not enrolled as a result of patient or clinician beliefs of 
preference were invited to participate in the parallel 
observational study. The parent or guardian of the child 
provided written consent. Children able to understand 
the study read an age-appropriate patient information 
leaflet and signed an age-appropriate consent form.
Randomisation and masking
Parents and children who consented to the study and 
agreed to randomisation were randomly assigned in a 
1:1 ratio to receive either amoxicillin or placebo. Treatment 
assignment was masked to investigators and participants. 
Invest igational medicinal product packs were indis-
tinguishable in appearance and packaging, and each was 
labelled with a unique identification number to maintain 
allocation concealment. A computer-generated random 
number list was provided by an independent statistician 
and kept only by the investigational medicinal product 
manufacturer. Random block sizes of 2 to 4 packs were 
used, with practice sites receiving whole blocks (multiple 
of six packs). Investigators randomised and dispensed by 
selecting the next sequentially numbered investigational 
medicinal product pack.
Procedures
Participants in the amoxicillin group received amoxicillin 
50mg/kg per day orally in three divided doses for 7 days 
and those in the placebo group received three oral doses 
per day for 7 days.
Amoxicillin was chosen because it is the first choice 
antibiotic in LRTI, and with current levels of intermediate 
resistance should cover most susceptible organisms.32 
The dose was chosen in line with guidance from the 
British National Formulary for children and was sup-
ported by a Monte Carlo simulation to achieve a minimal 
inhibitory concentration of around 1·5, to cover 
Haemophilus influenzae as well as intermediate resistant 
pneumococci for 90% of the intended population.32 We 
estimated that no fewer than 5 days of treatment at 
greater than minimal inhibitory concentration was 
needed to achieve bacterial eradication. A 7-day course 
was chosen to allow for poor adherence33 and on 
pragmatic grounds to match current practice at the time 
the study commenced to achieve greater clinician and 
parent acceptability; similar consensus was required for 
the related trial in adults.32 A 7-day course is also unlikely 
to result in more frequent side-effects (gastrointestinal; 
allergy) than a 5-day course.
The recruiting clinician completed a case report form 
of comorbidities, clinical signs, and the severity of 
baseline symptoms reported by the patient (rating each 
symptom as no problem, mild problem, moderate 
problem, or severe problem).32 Co-morbidity and the 
number of RTIs in the previous year were also 
documented, and pulse oximetry was done.
We chose throat swabs for microbiological sampling 
because of high pick-up rates and acceptability for 
children of this method.34 For parents and children 
willing to have a throat swab, a swab was taken and 
analysed in a central laboratory using multiplex PCR.
Parents kept a diary of symptoms and daily activities 
(including days away from work for parents) using a 
validated daily diary for at least 1 week and after that as 
long as symptoms persisted for up to 4 weeks after 
randomisation. The diary items recorded the severity of 
the following symptoms: cough, phlegm, shortness of 
breath, wheeze, blocked or runny nose, disturbed sleep, 
feeling generally unwell, fever, and interference with 
normal activities. Each symptom was scored from 0 to 6 
(0=no problem, 1=very little problem, 2=slight problem, 
3=moderately bad, 4=bad, 5=very bad, and 6=as bad as it 
could be).32,35 If the diary was not returned, a short 
questionnaire was sent by post, and if that was not 
returned, a phone call was made. All patients were 
requested to return to their practice after 1 month with 
medication bottles for assessment of medication use and 
clinical review.
Information on resource use was collected by notes 
review, including resource use for major adverse events 
(eg, anaphylaxis and progression of illness requiring 
hospital assessment or admission) at baseline and 
28 days after randomisation. This was used to assess 
NHS and social service use (primary care visits, 
community service, hospital inpatient and outpatient 
visits, and accident and emergency atten dances). 
Additional analyses to include out-of-pocket spending 
and parent or carer’s time off work in taking care of 
children were calculated. Unit costs of primary care 
consultation, community services, outpatient visits, and 
accident and emergency attendances were based on the 
Personal Social Services Research Unit. National 
reference costs were used to cost hospital stay on the 
basis of relevant diagnostic categories. Medications were 
priced on the basis of the NHS Drugs tariff. Cost per 
patient was calculated by the products of resource usage 
with corresponding unit costs. All costs were based on 
2018–19 prices.
Outcomes
The primary outcome was the duration of symptoms 
rated moderately bad or worse, as used in previous studies 
on acute LRTI,32,7 recorded in a validated daily diary for up 
to 28 days until the symptom resolved. The primary 
outcome matches parental concerns about more severe 
symptoms.32,33 The diary has previously been validated and 
was shown to be sensitive to change in both adults and 
children, and internally reliable (Cronbach’s α 0·75, ie, in 
optimal range).17,35 The estimates based on the diary can 
also be compared directly with the major definitive trial of 
antibiotics for adults with LRTI.32
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Secondary outcomes were severity of symptoms (cough, 
phlegm, shortness of breath, wheeze, blocked or runny 
nose, disturbed sleep, feeling generally unwell, fever, and 
interference with normal activities) each scored 0–6; total 
symptom duration, defined as the time from start of 
symptom to when severity reduced to 2 or less; 
reconsultation with new or worsening symp toms or 
complications; side-effects, including diarrhoea, rash, or 
nausea; health-care resource use; and adherence 
(number of doses taken). We chose to assess the severity 
of symptoms in the first 2–4 days after seeing the doctor 
(based on diary responses), because this is typically the 
period when symptoms are the most severe,17 when 
antibiotics might make a difference. Reconsultation with 
new or worsening symptoms or complications was 
documented on the basis of a structured notes review, 
which we have shown to be feasible and reliable36,37 and 
has demonstrated antibiotic effectiveness in the previous 
large trial in adults.32
We collected quality-adjusted life-years data in the diary 
but completion rates were very poor and they are not 
reported here.
Statistical analysis 
Balancing the threat posed by antibiotic resistance, a 3-day 
difference in symptom resolution (hazard ratio [HR] 1·7) 
for an illness lasting 14–21 days (ie, reducing the duration 
by 15–20%) was judged by the patient and public 
involvement team and agreed with the investigator team to 
be clinically important enough to warrant treatment. We 
originally estimated that 938 children were required (for 
α=0·01, 90% power, 80% follow-up) to detect an HR of 1·7 
for the primary outcome among any one of five equally 
prioritised clinical subgroups (chest signs; fever; physician 
rating of unwell; sputum or chest rattle; and shortness of 
breath), assuming any subgroup was 30% or more of the 
sample. The sample size calculation was revised after 
agreement with the funder, trial steering committee, and 
data monitoring safety committee based on (1) evidence 
from systematic reviews that abnormal chest signs are the 
most important driver for antibiotic prescriptions23 from six 
studies’ odds ratios for prescribing antibiotics ranging from 
3 to 20; and (2) using propor tions of subgroups observed 
(masked to randomisation group) in the penultimate 
season of the trial. We used a traditional approach of 
powering for the subgroup sizes, adjusting the α for 
multiple subgroups (chest signs subgroups α 0·05, other 
subgroups α 0·01), and calculating the total sample size 
required based on the proportion in the smallest subgroup. 
For the primary analysis for the chest signs subgroup, we 
estimated we would need 119 cases (for α 0·05, 80% power) 
assuming 40% of the trial cohort had chest signs (based on 
study data at the time when calculations were revised), or a 
total trial sample of 298 for 80% power and 398 for 
90% power. For other subgroups, we estimated we needed 
225 cases for 90% power and an α of 0·01.
Cox regression was used for the primary outcome 
(duration of symptoms rated moderately bad or worse in 
days) and for total symptom duration, adjusting for age, 
baseline symptom severity, previous duration of illness, 
and comorbidity. Linear regression was used for symp tom 
severity, and logistic regression for reconsultation, 
complications, and side-effects, adjusting for the same 
baseline covariates as in the primary analysis. Analysis was 
on an intention-to-treat basis, as randomised regardless of 
non-adherence or protocol deviations. Multiple imputation 
was chosen for the primary analysis and complete cases 
for a secondary analysis, because multiple imputation is 
generally more efficient than complete case analysis,38 and 
particularly important to control for potential attrition bias. 
Multiple imputation included those in the analysis model 
(age, comorbidity, previous duration of illness, and 
baseline severity) and significant predictors of missingness 
(parental qualifica tion) using 100 imputations.39 A 
complete-cases analysis and a complier average causal 
effect (CACE) analysis were performed as sensitivity 
analyses. Prespecified subgroup analyses were done for 
chest signs (α=0·05), sputum or chest rattle, history of 
fever, physician rating of unwell, shortness of breath, 
oxygen saturation below 95%, and STARWAVe clinical 
Figure 1: Trial profile
*61 younger than 6 months, 13 older than 12 years, 181 general practitioner judged as not having lower 
respiratory tract infection, 65 illness longer than 21 days, and eight other inclusion criteria not met. †25 had 
asthma or allergy-related cough, 83 general practitioner suspected viral infection, 26 had croup, 79 had previous 
antibiotics, three were allergic to penicillin, nine already enrolled or sibling already enrolled, 39 were admitted to 
hospital or too unwell, and 26 other exclusion criteria met (mostly other diagnoses, such as reflux, non-infective 
asthma exacerbation, or immunosuppression). ‡Denominators reflect number of participants for whom 
adherence data were available.
216 allocated to placebo
26 of 113‡ did not take placebo
211 analysed at baseline 
156 complete data primary outcome 
5 withdrew use of data
438 randomised 
1460 patients assessed for eligibility
55 lost to follow-up 
222 allocated to antibiotics
3 did not receive antibiotics 
(dispensing error)
21 of 119‡ did not take antibiotics
221 analysed at baseline 
161 complete data primary outcome 
1022 excluded
328 did not meet inclusion criteria*
144 declined to participate
290 met the exclusion criteria†
178 not recruited due to lack of 
ARTIC trained staff or staff time
 82 other reasons
60 lost to follow-up 
1 withdrew use of data
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prediction rule for hospital admission40 (all α=0·01). 
Analyses were done using Stata, version 16, and SPSS, 
version 26, and masked to group allocation.
Role of the funding source 
The funder of this study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
1460 participants were assessed for eligibility between 
Nov 9, 2016, and March 17, 2020. 438 patients were 
enrolled and randomly assigned to the antibiotics 
group (n=222) or placebo group (n=216). Six patients 
withdrew the use of their data and so could not be used 
in the intention-to-treat analysis. Thus, 432 participants 
were included in analyses: 221 in the antibiotics group 
and 211 in the placebo group (figure 1). 312 children 
were recruited to the parallel observational study 
(appendix p 10).
233 (54%) of 432 participants were male and 
199 (46%) were female, with a median age of 3·2 years 
(IQR 1·6–5·7), and 55 (13%) had a comorbidity (table 1). 






Female 99 (47%) 100 (45%)
Male 112 (53%) 121 (55%)
Age, years 3·1 (1·4–5·6) 3·2 (1·7–5·8)
Comorbidities 31 (15%) 24 (11%)
Asthma 27 (13%) 18 (8%)
Long-term illness 7/111 (6%) 13/120 (11%)
Hay fever or eczema 39/111 (35%) 44/121 (36%)
Family history of asthma 66/112 (59%) 81/117 (69%)
Breastfed at 3 months 49/110 (45%) 65/120 (54%)
Mother’s age, mean (SD; n) 34·8 (6·4; n=105) 34·9 (7·2; n=114)
Number of times had cough in 
past 12 months, mean (SD; n)
2·5 (2·3; n=110) 2·8 (2·8; n=112)
Previous influenza vaccine in 
past 12 months
55/200 (28%) 59/201 (29%)
Previous pneumococcal vaccine 
(booster) in past 12 months
61/200 (31%) 64/201 (32%)
Smoker in household
Yes 44 (21%) 50 (23%)
No 165 (78%) 166 (75%)
Don’t know 2 (1%) 5 (2%)
Number of children in home
1 87 (41%) 86 (39%)
2 73 (35%) 95 (43%)
3 35 (17%) 25 (11%)
4 13 (6%) 7 (3%)
5 or more 3 (1%) 8 (4%)
Parent highest qualification
Degree 78 (37%) 81 (37%)
Diploma 27 (13%) 23 (10%)
A level 23 (11%) 16 (7%)
GCSE or O level 20 (9%) 27 (12%)
None 10 (5%) 7 (3%)
Not given 42 (20%) 53 (24%)
Other 11 (5%) 14 (6%)
Ethnic group*
British, Irish, or other White 182 (86%) 189 (86%)
Mixed 8 (4%) 11 (5%)
South Asian 15 (7%) 14 (6%)
Other 4 (2%) 5 (2%)
Prefer not to say 1 (<1%) 2 (1%)
Data are n (%), median (IQR), or n/N (%), unless otherwise specified. *Data 
missing for one person in the placebo group.





Baseline severity* 1·6 (0·3) 1·6 (0·3)
Cough severity 1·9 (1·1) 2·0 (1·1)
Duration of symptoms rated moderately bad or 
worse, days
6 (3–10) 5 (3–10)
Prespecified subgroups
Abnormal chest signs† 72 (34%) 78 (35%)
Sputum or chest rattle 155/210 (74%) 170/219 (78%)
Fever during illness 161 (76%) 177 (80%)
Unwell according to physician‡ 141 (67%) 143 (65%)
Shortness of breath 95 (45%) 104 (47%)
Oxygen saturation low (<95%) 9/166 (5%) 13/170 (8%)
STARWAVe40§
Very low risk 110 (52%) 123 (56%)
Normal risk 95 (45%) 94 (43%)
High risk 6 (3%) 4 (2%)
Physician rating of unwell¶ 5·5 (1·7) 5·5 (1·6)
Parent rating of unwell¶ 3·8 (1·7) 3·7 (1·7)
Temperature, °C, mean (SD; n) 37·3 (0·8; n=208) 37·2 (0·8; n=220)
Oxygen saturation, %, mean (SD; n) 97·3 (1·6; n=166) 97·3 (1·6; n=170)
Heart rate, beats per min, mean (SD; n) 112·0 (20·3; n=207) 111·8 (17·9; n=213)
Respiratory rate, breaths per min, mean (SD; n) 24·8 (6·8; n=198) 25·4 (7·1; n=213)
Tachypnoea 25/198 (13%) 30/213 (14%)
Capillary refill >3 s 3 (1%) 2 (1%)
Consciousness||
Normal 203 (96%) 214 (97%)
Irritable 8 (4%) 5 (2%)
Drowsy 0 1 (<1%)
Ill appearance 48 (23%) 47 (21%)
Number of days unwell before seeing general 
practitioner, median (IQR; n)
5 (3–9; n=108) 5 (3–7; n=119)
Treated with over-the-counter medication 105/111 (95%) 107/121 (88%)
Data are mean (SD), median (IQR), n (%), or n/N (%), unless otherwise specified. *Scale of 1–4 as follows: 1=none, 
2=mild, 3=moderate, and 4=severe. †Includes wheeze, stridor, grunting, nasal flaring, intercostal or subcostal 
recession, crackles or crepitations, and bronchial breathing. ‡Dichotomised at ≥5. §STARWAVe prediction rule for 
hospital admission (short illness, temperature, age, recession, wheeze, asthma, and vomiting). ¶Scale of 0–10. ||Data 
missing for one person in the antibiotics group. 
Table 2: Illness presentation of randomised participants
See Online for appendix
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150 (35%) had abnormal chest signs, 325 (76%) of 429 
had sputum or chest rattle (some data were missing from 
case report forms so these individuals are not included in 
the total), 338 (78%) had a fever during the illness, 
284 (66%) were categorised as unwell according to the 
physician rating (rating of ≥5 on a scale of 1–10), and 
199 (46%) had shortness of breath (table 2). 22 (7%) of 
336 with available data had oxygen saturation less 
than 95%. According to the STARWAVe prediction rule,40 
233 (54%) were at very low risk of hospital admission, 
189 (44%) were at normal risk, and ten (2%) were at 
high risk of hospital admission. The key baseline 
characteristics were similar across the two randomised 
groups (tables 1, 2).
Of those who reported which medication they thought 
their child had received, 47 (47%) of 101 in the antibiotics 
group and 33 (39%) of 84 in the placebo group thought 
their child had received antibiotics.
Complete data were available on symptom duration 
for 317 (73%) participants, on symptom severity for 
298 (69%), on reconsultation with new or worsening 
symptoms for 401 (93%), on complications for 415 (96%), 
and on side-effects for 310 (72%) participants (table 3). 
For the key subgroups, we had complete data for 
109 children in the chest-signs subgroup, 247 for fever, 
208 for physician rating of being unwell, and 146 for 
shortness of breath. The primary analysis for each 
subgroup used imputed data, and a secondary analysis 
was done using complete cases (appendix pp 3–4)
The median duration of moderately bad or worse 
symptoms was similar between groups (5 days 
[IQR 4–11] in antibiotics group vs 6 days [4–15] in the 
placebo group; HR 1·13 [95% CI 0·90–1·42]; table 4, 
figure 2). Although we did not achieve adequate power 
for the complete case analysis for the chest signs 
subgroup, none of the prespecified clinical subgroups 
nor additional post-hoc exploratory subgroups (low 
oxygen saturation, STARWAVe categories, or adjustment 
for asthma and vaccination status) modified the effect of 
treatment on duration of moderately bad or worse 
symptoms (table 5).
There was a small significant difference between the 
groups in symptom severity on days 2–4 after seeing the 
doctor (1·8 [SD 1·0] in the antibiotics group vs 2·1 [1·1] in 
the placebo group; mean difference –0·28 [95% CI 
–0·51 to –0·04]; table 4), which was equivalent to less 
than one child in three rating symptoms a slight problem 
(score 2) rather than very little problem (score 1).
The median duration of symptoms until rated absent 
or very little problem was also similar between the groups 
(7 days [IQR 4–17] in the antibiotics group vs 8 days [5–20] 
in the placebo group; HR 1·09 [95% CI 0·86–1·38]; 
table 4). The number of participants reconsulting with 
new or worsening symptoms was 60 (30%) of 202 in the 
antibiotics group compared with 76 (38%) of 199 in the 
placebo group (risk ratio 0·80 [95% CI 0·58–1·05]). 
Complications were uncommon (five [2%] of 211 vs 
Placebo group Antibiotics group
Duration of moderately bad or worse (score ≥3) symptoms in 
days, median (IQR; n)
6 (4–15; n=156) 5 (4–11; n=161)
Symptom severity, mean (SD; n) 2·1 (1·1; n=149) 1·8 (1·0; n=149)
Duration of symptoms until very little problem (score 1) in days, 
median (IQR; n)
8 (5–20; n=156) 7 (4–17; n=161)
Return with new or worsening symptoms 76/199 (38%) 60/202 (30%)
Assessment or admission needed in hospital* 4/204 (2%) 5/211 (2%)
Side-effects 52/153 (34%) 60/157 (38%)
Diarrhoea 26/88 (30%) 24/98 (24%)
Nausea 32/92 (35%) 35/102 (34%)
Rash 20/91 (22%) 25/99 (25%)
Data are n/N (%) unless otherwise stated. Symptom severity on a scale of 0–6 as follows: 0=no problem, 1=very little 
problem, 2=slight problem, 3=moderately bad, 4=bad, 5=very bad, and 6=as bad as it could be. *Within 1 month of 
index consultation.







Adjusted* treatment estimate 
(95% CI)
Duration of moderately bad or worse 
(score ≥3) symptoms in days
6 (4 to 15) 5 (4 to 11) Hazard ratio 1·13 (0·90 to 1·42)
Symptom severity 2·1 (1·1) 1·8 (1·1) Difference –0·28 (–0·51 to –0·04)
Duration of symptoms until very little 
problem (score 1) in days
8 (5 to 19) 7 (4 to 17) Hazard ratio 1·09 (0·86 to 1·38)
Return with new or worsening 
symptoms
38% 30% Odds ratio 0·71 (0·46 to 1·09); 
risk ratio 0·80 (0·58 to 1·05)
Assessment or admission needed in 
hospital†
2% 2% Odds ratio 1·24 (0·32 to 4·78); 
risk ratio 1·23 (0·32 to 4·44)
Side-effects 33% 39% Odds ratio 1·33 (0·81 to 2·17); 
risk ratio 1·20 (0·87 to 1·55)
Data are median (IQR), mean (SD), or n (%). *Adjusted for previous duration of illness, baseline severity, age, and 
comorbidity. †Assessment or admission needed in hospital within 1 month of index consultation (appendix p 1). 
Table 4: Effectiveness of antibiotics on primary and secondary outcomes (imputed)
Figure 2: Kaplan-Meier curve of duration of moderately bad or worse symptoms in days
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four [2%] of 204; risk ratio 1·23 [0·32–4·44]). The 
numbers of participants with side-effects were similar 
(60 [38%] of 157 vs 52 [34%] of 153; risk ratio 1·20 
[0·87–1·55]). The number of complications and hospital 
admissions in both groups were low, and similar between 
groups (appendix p 1).
The main analyses (tables 4, 5) were calculated based 
on 100 multiply-imputed datasets. Complete-case 
analyses gave very similar results (appendix pp 3–4).
The treatment effects for all outcomes were similar for 
most subgroups (none of the interaction terms were 
significant), but the effect of antibiotics was slightly, but 
not significantly, greater among those with fever or those 
who were unwell (appendix pp 5–6). Reconsultations 
with antibiotics were slightly more frequent among the 
less unwell children (appendix p 7).
232 (54%) participants provided data on adherence 
to medication. Of those who reported medication 
adherence, 98 (82%) of 119 in the antibiotics group and 
87 (77%) of 113 in the placebo group took at least 11 doses 
of medication over days 1–5. A per-protocol analysis 
including only those children who were recorded as 
having taken 11 doses of medication over 1–5 days 
documented no significant difference in the duration of 
moderately bad or worse (score ≥3) symptoms, with an 
HR of 1·06 (95% CI 0·77–1·46; appendix p 2). A CACE 
analysis gave an unadjusted HR for the duration of 
moderately bad or worse (≥3) symptoms of 1·31 (95% CI 
0·90–1·89; which is similar to the unadjusted primary 
analysis HR of 1·21 [95% CI 0·95–1·53]).
A fuller economic evaluation using the limited quality 
of life data and cost data will be published elsewhere. 
The key finding was that only small and non-significant 
differences in costs were observed. Slightly higher total 
NHS costs per child were documented in the antibiotic 
group (£29·40 in the antibiotic group vs £25·80 in the 
placebo group). The cost of antibiotics was low at around 
10%, the bulk of NHS costs being from reconsultations 
and referrals. The societal costs due to time off work or 
privately purchased remedies were also similar between 
groups (£32·90 vs £32·70; appendix p 8).
The microbiological analysis documented similar 
numbers of potential bacterial and viral pathogens 
(appendix p 9). A small number (two in the placebo 
group and five in the antibiotics group) of bacterial 
pathogens were identified that would not be expected 
to respond to amoxicillin or were not implicated in 
LRTI (Chlamydia pneumoniae, Mycoplasma pneu­
moniae, Bordetella pertussis, Streptococcus pyogenes, and 
Fusobacterium necrophorum). There was no evidence 




n Median (IQR) n Median (IQR)
Abnormal chest signs
Yes 54 6·0 (4·0–16·0) 52 6·0 (4·0–15·0) 0·84 (0·52–1·36) 0·97 (0·65–1·43)
No 102 7·0 (4·0–15·0) 109 5·0 (3·0–11·0) ·· 1·21 (0·91–1·60)
Sputum
Yes 115 7·0 (4·0–16·0) 124 5·0 (4·0–14·0) 1·11 (0·55–2·26) 1·16 (0·83–1·64)
No 41 5·0 (4·0–14·0) 36 5·0 (3·0–10·0) ·· 0·99 (0·52–1·90)
Fever
Yes 115 6·0 (4·0–16·0) 131 5·0 (3·0–10·0) 1·45 (0·71–2·98) 1·23 (0·88–1·73)
No 41 7·0 (4·0–13·0) 30 7·0 (4·0–26·0) ·· 0·78 (0·40–1·53)
Physician rating of unwell‡
Yes 104 6·0 (4·0–15·5) 101 5·0 (3·0–10·0) 1·32 (0·71–2·46) 1·25 (0·85–1·83)
No 52 8·0 (4·0–14·5) 60 6·0 (4·0–16·0) ·· 0·96 (0·58–1·58)
Shortness of breath
Yes 77 6·0 (4·0–11·0) 71 5·0 (3·0–14·0) 0·96 (0·54–1·73) 1·13 (0·72–1·77)
No 79 7·0 (4·0–18·5) 90 5·5 (4·0–11·0) ·· 1·17 (0·78–1·75)
Oxygen saturation low
Yes 7 11·0 (6·0–18·0) 8 8·0 (4·0–20·0) 0·95 (0·23–3·94) 1·20 (0·24–5·93)
No 119 6·0 (4·0–15·0) 116 5·0 (3·5–10·0) ·· 1·11 (0·78–1·57)
STARWAVe40§
Very low risk 78 7·0 (4·0–17·0) 93 5·0 (4·0–10·0) 0·77 (0·45–1·30) 1·27 (0·84–1·91)
Normal risk 72 6·0 (4·0–11·5) 65 6·0 (3·0–14·0) ·· 1·06 (0·67–1·66)
High risk¶ 6 ·· 3 ·· ·· ··
*95% CI for the abnormal chest signs subgroup. †Adjusted for previous duration of illness, baseline severity, age, and comorbidity. ‡Scale of 1–10, dichotomised at ≥5. 
§STARWAVe prediction rule for hospital admission (short illness, temperature, age, recession, wheeze, asthma, and vomiting). ¶Too few data to obtain reliable estimates.
Table 5: Duration of moderately bad or worse symptoms by subgroup (imputed)
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of a differential effect of antibiotics where bacteria 
sensitive to amoxicillin (H influenzae, Moraxella 
catarrhalis, and Streptococcus pneumoniae) were present 
(appendix p 9).
The children in the observational study were similar to 
the trial, although the former included more children 
who had chest signs (appendix pp 10–12).
Discussion 
Our results showed that for children presenting to 
primary care with uncomplicated acute LRTI, there is 
unlikely to be a clinically relevant effect of amoxicillin 
treatment on symptom burden, both overall and for key 
patient subgroups, in whom antibiotics are commonly 
prescribed. There was also no evidence of additional 
complications when antibiotics are not prescribed.
ARTIC PC is one of the very few studies to report on the 
effectiveness of prescribing antibiotics among younger 
children presenting with chest infections in primary 
care. It was designed to be able to detect a clinically 
important 3-day improvement in symptom duration (an 
HR of 1·7)—about a 15% difference considering a total 
illness duration of 20–25 days documented by a sys-
tematic review,41 or roughly a 20% improvement for an 
illness lasting 14 days based on the placebo group of our 
trial. A 3-day improvement in a subgroup was judged to 
be important enough to be worth prescribing an 
antibiotic, given the public health danger from antibiotic 
resistance.2,3 We used the most patient-relevant outcome 
(parent-reported symptoms), and documented 
complications (ie, the progression of illness requiring 
hospital assessment or admission). The study confirmed 
that  complications are uncommon but it was not 
specifically powered to assess complications (a trial 
of several thousand children would be needed), nor 
reconsultations, nor microbiological subgroups. The 
sample size estimate was modified during the trial on the 
basis of a systematic review of the evidence, and informed 
by the proportions of subgroups observed during the 
penultimate season of the trial (masked to group assign-
ment). In the final sample, imputed and complete 
cases analyses were adequately powered overall and for 
subgroups, except for the complete case analysis in the 
chest sign subgroup–in part due to slightly fewer children 
having chest signs than expected and the COVID-19 
pandemic prematurely ending recruitment. However, 
the estimates for the primary outcome for complete and 
imputed cases in the chest signs subgroup were very 
similar (6 days in the antibiotic group and placebo group 
in both analyses), the HRs near unity (0·91 and 0·97), 
and the upper 95% CIs of the HRs (1·41 and 1·43) suggest 
the benefit for children with chest signs is unlikely to be 
more than 2 days—ie, not clinically important. The 
follow-up rate of 73% (317 of 432) raises concern about 
possible attrition bias, but the estimates when using 
imputed data are very similar to the complete case 
analysis, so attrition bias is unlikely. Although the study 
was placebo controlled, the study was at the pragmatic 
end of the spectrum in that there was no close monitoring 
of parents and children: parents behaved as they might in 
practice as to whether they gave their child medication, 
and per-protocol and CACE analyses provided similar 
estimates to the total trial population. The antibiotic 
(amoxicillin) was chosen because it is the first-choice 
antibiotic in UK national guidance for use in LRTIs 
among children (NICE guidance or antimicrobial 
prescribing guidelines). The trial population was similar 
to children recruited to the smaller parallel observational 
study, but compared with large representative observa-
tional cohorts, this trial population had slightly more 
severe clinical presentation.40 Thus, if anything we are 
likely to have overestimated the effect of antibiotics in 
the UK setting, but results might not generalise to other 
settings—eg, countries with very different diagnostic 
approaches, prescription rates, complication rates (eg, 
low-income and middle-income countries [LMICs]), or 
distribution of pathogens.
Only one trial in the Cochrane review of antibiotics for 
acute bronchitis included children as young as 3 years of 
age presenting with uncomplicated acute chest 
infections.17,19 In that trial, there were only 100 children 
aged 12 years or younger, and the estimate of immediate 
antibiotics compared with no offer of antibiotics on 
symptom duration (HR 1·00) and symptom severity 
(mean reduction –0·3 on a scale of 0–6) was similar to 
the non-significant result of the whole trial cohort.17 
These results are consistent with the results of the 
current study. A Cochrane review found inconclusive 
evidence for the effect of antibiotics in preventing RTIs,42 
but a more recent trial of azithromycin used in early 
infections was effective in preventing severe illness 
among preschool children with recurrent infection43 
(from 8% to 5%), although concern remains about the 
longer-term effects on antibiotic resistance from the use 
of long-acting macrolides.6 A placebo-controlled trial of 
antibiotic versus placebo for pneumonia in young 
children in an LMIC setting found low failure rates in 
both placebo (5%) and antibiotic (3%) groups,44 and a 
5-day course is equivalent to 10 days for community-
acquired pneumonia.45
Our results suggest that antibiotics do not provide a 
clinically important benefit on average for symptom 
reduction nor symptom severity. The question remains 
whether there are some children who receive a 
meaningful benefit, but the benefit is diluted by large 
numbers of children who receive no benefit. We explored 
this hypothesis by conducting subgroup analyses in five 
prespecified subgroups. Our subgroup analysis results 
suggest that none of the groups we specified were likely 
to achieve substantial benefits in terms of symptomatic 
improvement from antibiotics, although we did not have 
the power to exclude more moderate benefits. By 
contrast, the average benefit from antibiotics in the 
general population might be even weaker than our 
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findings suggest. We had significantly fewer children 
with a very low-risk STARWAVe score in this study 
compared with the STARWAVe observational study, 
which recruited a representative sample of children with 
RTIs from the population (67% had a very low risk 
compared with 54% in our trial).40 This lower proportion 
of children with very low risk in our trial then in the 
STARWAVe observational study suggests that our trial 
successfully recruited more unwell children, in whom 
antibiotics might be expected to be more effective, and 
that the average effect of antibiotics in a more 
generalisable low-risk population is likely to be even 
weaker than reported here. Although the analysis was 
underpowered, there was no clear signal for selective 
benefit among children where pathogenic bacteria were 
isolated, which could possibly be due to high carriage 
rates among children rather than true infection. The 
estimates of resource use suggest that not only are 
consultation, referral, and hospital admission costs 
considerable,46 but societal costs are high. Antibiotic 
prescribing was not associated with health or societal 
resource savings, and if anything resulted in slightly 
higher costs. If the costs of antibiotic resistance were 
included, the adverse effect on health and societal 
resource use would be even higher.7
 Similar to adults, antibiotics are unlikely to make a 
clinically important difference to the symptom burden 
for uncomplicated lower respiratory tract infections 
in children—both overall, and for the key clinical 
subgroups where antibiotic prescribing is most common. 
Unless pneumonia is suspected, clinicians should 
provide so-called safety-netting advice (ie, explain what 
illness course to expect and when it would be necessary 
to reattend) but not prescribe antibiotics for most 
children presenting with chest infections.
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